A carregar...
Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
BACKGROUND: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued. Fingolimod is seen as an alternative, but there are no long-term analyses of the effi...
Na minha lista:
| Publicado no: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088480/ https://ncbi.nlm.nih.gov/pubmed/30116299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286418791103 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|